According to Reuters, the FDA has granted approval to Rockwell Medical Inc. for a drug used to treat iron loss in patients on dialysis. Anemia is commonly found in patients with chronic kidney disease who are on dialysis. Triferic replaces the 5 to 7 mg of iron lost during treatment, either due to dialysis itself or because of the patient’s inability to produce erythropoietin. The medication simply gets added to the dialysis solution, making it the first drug that eliminates the need for intravenous iron which is less efficient. The drug company values the global market for the drug at more than $1 billion, with an annual growth of 6-8 percent.